Welcome to our dedicated page for Klotho Neurosciences SEC filings (Ticker: KLTOW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Klotho Neurosciences's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Klotho Neurosciences's regulatory disclosures and financial reporting.
Greenland Mines Ltd has received an additional 180-day period, through September 14, 2026, to regain compliance with Nasdaq’s minimum $1.00 per share bid price requirement. The company must achieve a closing bid of at least $1.00 for 10 consecutive business days within this window or its common stock will be subject to delisting from Nasdaq.
The extension reflects that Greenland Mines currently meets all other Nasdaq listing standards, including market value of publicly held shares. The company highlights two divisions: Natural Resources, anchored by the Skaergaard Project in Southeast Greenland with a 2022 NI 43-101 Indicated and Inferred Mineral Resource of 25.4 Moz PdEq and 23.5 Moz AuEq, and Cell and Gene Therapy, including the KLTO-202 program for ALS.
Greenland Mines Ltd, formerly Klotho Neurosciences, Inc., has changed its corporate name and will trade on Nasdaq under the new ticker GRML, replacing KLTO. The name change became effective on March 11, 2026, with trading under GRML starting March 12, 2026.
The company now highlights two operating divisions: a Natural Resources unit focused on the Skaergaard Project in Southeast Greenland and a Cell and Gene Therapy unit that includes the KLTO-202 program for ALS. Through a recent acquisition of Greenland Mines Corp., it holds an 80% interest and an option to acquire the remaining 20% of Skaergaard, which has a 2022 NI 43-101 Indicated and Inferred Mineral Resource of 25.4 Moz PdEq and 23.5 Moz AuEq with an illustrative gross in-situ metal value of about $68 billion based on February 2026 metal prices. The company stresses that these are Mineral Resources rather than reserves and that no economic study has yet demonstrated project viability.
Greenland Mines Ltd reports that Strategic EP, LLC and Alexander Chase Deitch collectively beneficially own 6,687,472 shares of Common Stock, representing 5.5% of the class as of 03/04/2026. The filing states the holdings reflect shared voting and shared dispositive power of 6,687,472 shares.
The Reporting Persons also hold warrants to purchase 6,687,472 shares, but exercise of those warrants is conditioned on stockholder approval and therefore those underlying shares are not treated as beneficially owned under Rule 13d-3. The reported outstanding share base is 121,238,660 shares.
Greenland Mines Ltd, formerly Klotho Neurosciences, is hosting a publicly accessible investor webcast on March 12, 2026, to present its new strategy and assets. The company recently completed the acquisition of Greenland Mines on March 4, 2026, paying consideration in convertible preferred equity subject to shareholder approval.
Following the deal, the business now operates two divisions: Natural Resources and Cell and Gene Therapy. Greenland Mines owns 80% of the Skaergaard Project in southeast Greenland, with an option on the remaining 20%. A 2022 NI 43-101 report shows 25.4 Moz PdEq and 23.5 Moz AuEq, with an estimated in-situ resource value of about $68 billion at February 2026 metal prices. A new drilling and development program aims to double the resource to roughly 50 million contained ounces of gold, palladium, and platinum.
Klotho Neurosciences, Inc. reported that Chief Financial Officer Jeff LeBlanc acquired 2,500,000 shares of common stock on a grant/award basis. The shares were received at a price of $0.00 per share as a grant under the company’s Equity Incentive Plan, meaning no cash purchase was involved.
Following this equity award, LeBlanc directly holds 3,420,342 common shares of Klotho Neurosciences. This filing records an increase in his equity-based compensation and ownership stake through the company’s incentive program.
Klotho Neurosciences, Inc. director El-Dada Riad Hussein reported receiving a grant of 350,000 shares of Common Stock on March 4, 2026. The shares were awarded under the company’s Equity Incentive Plan and were acquired at a stated price of $0.00 per share.
ZENTMAN SAMUEL M reported acquisition or exercise transactions in this Form 4 filing.
Klotho Neurosciences, Inc. director Samuel M. Zentman reported receiving a grant of 350,000 shares of Common Stock on March 4, 2026. The shares were awarded at a stated price of $0.00 per share as a grant under the company’s Equity Incentive Plan.
Following this equity award, Zentman’s directly held Common Stock increased to 1,086,440 shares. This filing reflects a non-cash stock grant that further aligns the director’s ownership with the company’s performance.
Klotho Neurosciences, Inc. reported that director Shalom Hirschman acquired 350,000 shares of Common Stock on March 4, 2026. The shares were received as a grant under the company’s Equity Incentive Plan and carried a stated price of $0.00 per share.
Following this equity award, Hirschman’s direct ownership increased to 908,873 shares of Common Stock, according to the Form 4 disclosure.
McGarity Jon reported acquisition or exercise transactions in this Form 4 filing.
Klotho Neurosciences, Inc. director Jon McGarity reported receiving a grant of 350,000 shares of Common Stock on March 4, 2026. The shares were granted under the company’s Equity Incentive Plan and carried a reported price of $0.00 per share, indicating a non-cash equity award. Following this grant, McGarity’s directly held Common Stock increased to 411,277 shares, aligning his compensation more closely with shareholder interests through additional stock-based incentives.